SRC Sigmaroc Plc

 
TIDMASM 
 
London,  UK, Cambridge,  MA, and  Barcelona, Spain:  14 June 2010 -  Cancer drug 
developer   Antisoma   plc   (LSE:   ASM;  USOTC:  ATSMY)  announces  that  five 
presentations,  including an  oral presentation,  supporting the  development of 
AS1413  (amonafide L-malate) and  AS1411 were presented  over the weekend at the 
European Hematology Association (EHA) meeting in Barcelona. All are available on 
Antisoma's   website   at   http://www.antisoma.com  <http://www.antisoma.com/>. 
Details of the presentations can be found below. 
 
Enquiries: 
Antisoma plc: 
Glyn Edwards, CEO 
Daniel Elger, VP Marketing & Communications               +44 (0)7909 915 068 
 
Details of the presentations at EHA 
 
AS1413 
#0079  The presence of P-glycoprotein (MDR1) affects the ability of AML patients 
to  achieve complete  remission; results  of a  meta-analysis of the literature; 
Marie et al. (poster) 
 
#0650  Treatment-related  AML  and  AML  evolving  from  MDS:  Similar  outcomes 
following treatment with amonafide + cytarabine; Sekeres et al. (poster) 
 
#0457  The novel DNA intercalator amonafide  (AS1413) disrupts the cell cycle by 
mechanisms distinct from those of Topo II inhibitors daunorubicin and etoposide; 
Senderovich et al. (poster) 
 
AS1411 
#1119  Long-term outcomes  of responders  in a  randomized, controlled  phase II 
trial of aptamer AS1411 in AML; Stuart et al. (oral presentation) 
 
#0643  Gene expression analysis in AML cell line MV4-11 following treatment with 
the anti-cancer aptamer AS1411 Senderovich et al. (poster) 
 
About AS1413 (amonafide L-malate) 
AS1413 (amonafide L-malate) was added to Antisoma's pipeline through the 
acquisition of Xanthus Pharmaceuticals, Inc. in June 2008. AS1413 is a novel DNA 
intercalator that induces apoptotic signalling by blocking topoisomerase II 
binding to DNA. This differs from the action of classical topoisomerase II 
inhibitors, which induce apoptosis by causing extensive DNA damage. A further 
distinctive feature of AS1413 is its ability to evade Pgp and related 
transporters responsible for multi-drug resistance (MDR). A pivotal phase III 
trial (ACCEDE) is evaluating AS1413 as a treatment for secondary AML, a 
condition often associated with MDR and in which outcomes with currently 
available treatments are poor. Earlier this month, the US Food and Drug 
Administration granted AS1413 Fast Track status for the treatment of secondary 
AML. 
 
About AS1411 
AS1411 was originally developed by Dr Paula Bates, Dr John Trent and Prof. 
Donald Miller at the University of Alabama and later at the University of 
Louisville. Antisoma added AS1411 to its pipeline when it acquired the 
Louisville-based company Aptamera Inc. in 2005.  AS1411 belongs to a new type of 
drugs called aptamers. These are short pieces of DNA or RNA that fold into 
three-dimensional structures capable of targeting particular proteins. AS1411 is 
a DNA aptamer that binds to nucleolin, a protein expressed in the nucleus of all 
cells but which in cancer cells is also exposed on the cell surface, providing a 
basis for specific targeting by AS1411. When AS1411 binds to nucleolin on cancer 
cells, it is internalised and causes apoptosis through interference with various 
functions of nucleolin. AS1411 is being evaluated in a phase IIb trial in 
patients with relapsed and refractory AML. 
 
About Antisoma 
Antisoma is a London Stock Exchange-listed biopharmaceutical company that 
develops novel products for the treatment of cancer. The Company has operations 
in the UK and the US. Please visitwww.antisoma.com <http://www.antisoma.com/> 
for further information about Antisoma. 
 
 
 
[HUG#1423501] 
 

Sigmaroc (LSE:SRC)
Historical Stock Chart
From Mar 2024 to Apr 2024

Sigmaroc (LSE:SRC)
Historical Stock Chart
From Apr 2023 to Apr 2024